$105.46
-0.46[-0.43%]
At close: May 3
$105.46
0[0.00%]
After Hours: 6:48PM EDT
Abbott Laboratories
(NYSE:ABT)Abbott Laboratories Stock (NYSE:ABT), Analyst Ratings, Price Targets, Predictions
Abbott Laboratories has a consensus price target of $124.1, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Barclays, RBC Capital, and Evercore ISI Group on April 22, 2024, April 18, 2024, and April 4, 2024. With an average price target of $130 between Barclays, RBC Capital, and Evercore ISI Group, there's an implied 23.27% upside for Abbott Laboratories from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
RBC Capital
Evercore ISI Group
Citigroup
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Abbott Laboratories
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 32.75% | Barclays | Matt Miksic | $141 → $140 | Maintains | Overweight | Get Alert |
| 04/18/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 18.53% | RBC Capital | Shagun Singh | $128 → $125 | Maintains | Outperform | Get Alert |
| 04/04/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 18.53% | Evercore ISI Group | Vijay Kumar | $120 → $125 | Maintains | Outperform | Get Alert |
| 04/03/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 21.37% | Citigroup | Joanne Wuensch | $126 → $128 | Maintains | Buy | Get Alert |
| 02/14/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 21.37% | RBC Capital | Shagun Singh | → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/26/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 33.7% | Barclays | Matt Miksic | $133 → $141 | Maintains | Overweight | Get Alert |
| 01/25/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 19.48% | Citigroup | Joanne Wuensch | $123 → $126 | Maintains | Buy | Get Alert |
| 01/25/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 21.37% | RBC Capital | Shagun Singh | → $128 | Reiterates | Outperform → Outperform | Get Alert |
| 01/25/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 20.42% | Raymond James | Jayson Bedford | $124 → $127 | Maintains | Outperform | Get Alert |
| 01/11/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 21.37% | RBC Capital | Shagun Singh | $119 → $128 | Maintains | Outperform | Get Alert |
| 01/03/2024 | ABT | Buy Now | Abbott Laboratories | $105.46 | 17.58% | Raymond James | Jayson Bedford | $110 → $124 | Maintains | Outperform | Get Alert |
| 12/13/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 14.74% | Wells Fargo | Lawrence Biegelsen | $116 → $121 | Maintains | Overweight | Get Alert |
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 1.46% | Morgan Stanley | David Lewis | $112 → $107 | Maintains | Equal-Weight | Get Alert |
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 9.99% | Wells Fargo | Lawrence Biegelsen | $136 → $116 | Maintains | Overweight | Get Alert |
| 10/19/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 4.3% | Raymond James | Jayson Bedford | $123 → $110 | Maintains | Outperform | Get Alert |
| 07/24/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 25.17% | Barclays | Matt Miksic | $127 → $132 | Maintains | Overweight | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 6.2% | Morgan Stanley | David Lewis | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | 9.05% | Mizuho | Anthony Petrone | $110 → $115 | Assumes | Neutral → Neutral | Get Alert |
| 07/21/2023 | ABT | Buy Now | Abbott Laboratories | $105.46 | — | Wolfe Research | Mike Polark | — | Upgrade | Underperform → Peer Perform | Get Alert |
FAQ
What is the target price for Abbott Laboratories (ABT)?
The latest price target for Abbott Laboratories (NYSE: ABT) was reported by Barclays on April 22, 2024. The analyst firm set a price target for $140.00 expecting ABT to rise to within 12 months (a possible 32.75% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abbott Laboratories (ABT)?
The latest analyst rating for Abbott Laboratories (NYSE: ABT) was provided by Barclays, and Abbott Laboratories maintained their overweight rating.
When was the last upgrade for Abbott Laboratories (ABT)?
The last upgrade for Abbott Laboratories happened on July 21, 2023 when Wolfe Research raised their price target to N/A. Wolfe Research previously had an underperform for Abbott Laboratories.
When was the last downgrade for Abbott Laboratories (ABT)?
There is no last downgrade for Abbott Laboratories.
When is the next analyst rating going to be posted or updated for Abbott Laboratories (ABT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Abbott Laboratories (ABT) correct?
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $141.00 to $140.00. The current price Abbott Laboratories (ABT) is trading at is $105.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.